MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1097/js9.0000000000004089

Медицинская библиотека · International journal of surgery (London, England) · 2025

Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact.

Fan Hongjie, Xu Tao, Zeng Yulan, Hu Jihong, Ding Rong, Li Xinghai, Zhao Fenhua, Fu Chunlong, Cun Jiangping, Li An, Xie Xuancheng, Xu Shufeng, Zou Jiahua, Tang Bufu, Xia Xiangwen

СтатьяМногоцентровое исследованиеПеревод пока не подготовлен

Аннотация

BACKGROUND

To investigate the prognostic value of RAS mutation status and subtypes in colorectal lung metastases (CRLM) patients undergoing image-guided thermal ablation (IGTA), and to evaluate survival outcomes under different systemic therapy regimens.

MATERIALS AND

METHODS

In this multicenter retrospective-prospective cohort study, 387 patients with CRLM who received percutaneous IGTA between March 2014 and December 2022 were included. Patients were stratified by RAS genotype (KRAS/NRAS wild-type vs mutant). Survival outcomes including local tumor progression-free survival (LTPFS), progression-free survival (PFS), and overall survival (OS) were analyzed using Cox regression. Subgroup analyses were conducted based on chemotherapy regimens and targeted agents.

RESULTS

The 3-year LTP rate was significantly higher in KRAS-mutant patients (25.0%) than wild-type (15.0%). KRAS mutation, lesion diameter ≥20 mm, and elevated CEA were independent risk factors for LTP. Median PFS was 16.0 months; KRAS mutations predicted inferior PFS (13.3% vs 32.8% at 3 years). Median OS was significantly reduced in both KRAS (17.9 vs 56.8 months) and NRAS-mutant patients (22.1 vs 53.8 months). Among KRAS-mutant patients, FOLFOX plus bevacizumab yielded better OS than cetuximab.

CONCLUSION

RAS mutations are independent predictors of poor local control and survival after IGTA in CRLM. Evaluate interactions between RAS genotype and commonly used targeted agents in the peri-ablative setting. These integrated, real-world insights support the development of genotype-guided ablation planning and peri-ablative systemic therapy strategies.

Для цитирования: Fan Hongjie, Xu Tao, Zeng Yulan, Hu Jihong, Ding Rong, Li Xinghai, Zhao Fenhua, Fu Chunlong, Cun Jiangping, Li An, Xie Xuancheng, Xu Shufeng, Zou Jiahua, Tang Bufu, Xia Xiangwen. Combating colorectal lung metastases via systemic therapy and thermal ablation: RAS mutation impact.. International journal of surgery (London, England). 2025. DOI: 10.1097/js9.0000000000004089.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.